Business, energy, technology, markets and global industry news from Business News Today

Organon

PharmaDeviceNews Organon
A dermatologist evaluates atopic dermatitis during a clinical consultation as Organon’s Phase 3 pooled analysis shows early, consistent improvements with VTAMA tapinarof cream across pediatric age groups and adults. Representative image.
Pharma & Biotech

Organon VTAMA analysis shows consistent atopic dermatitis efficacy across children and adults

Organon’s VTAMA Phase 3 analysis shows consistent atopic dermatitis responses across children and adults, strengthening its clinical case.

Read More
Representative image of a contraceptive implant applicator in a clinical setting. This visual highlights the real-world procedure behind long-acting birth control methods like NEXPLANON, recently approved for five-year use by the FDA. The image reflects themes of provider training, regulatory oversight, and expanding access—central to Organon’s latest label update and REMS rollout.
Pharma & Biotech

Organon’s NEXPLANON gains FDA nod for five-year use, but REMS adds new provider hurdles

Organon’s etonogestrel implant NEXPLANON has received FDA approval for extended use up to five years, marking a significant regulatory win for the women’s health–focused pharmaceutical company. The decision, which comes via a supplemental new drug application (sNDA), builds on existing data supporting the implant’s high efficacy and safety profile and broadens its potential utility among

Read More
Pharma & Biotech

Organon’s NEXPLANON earns five-year approval: How this changes the LARC landscape

FDA approves NEXPLANON for five years of use with REMS program. Find out how this reshapes contraceptive access, safety, and policy impact.

Read More